An updated patent review of small-molecule ROS1 kinase inhibitors (2015–2021)

References

• Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta. 2009;1795(1):37–52.
   PubMed Web of Science ®Google Scholar
• Roskoski R. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. Pharmacol Res. 2017;121:202–212.
   PubMed Web of Science ®Google Scholar
• Birchmeier C, O’Neill K, Riggs M, et al. Characterization of ROS1 cDNA from a human glioblastoma cell line. Proceedings of the National Academy of Sciences of the United States of America. 1990;87(12):4799–4803.
   PubMed Web of Science ®Google Scholar
• Robinson DR, Wu Y-M, Lin S-F. The protein tyrosine kinase family of the human genome.Oncogene. 2000 [2000 Nov 20];19(49):5548–5557.
   PubMed Web of Science ®Google Scholar
• Davies KD, Doebele RC. Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res. 2013;19(15):4040–4045.
   PubMed Web of Science ®Google Scholar
• Rimkunas VM, Crosby KE, Li D, et al. Analysis of receptor tyrosine kinase ROS1-Positive tumors in non–small cell lung cancer: identification of a FIG-ROS1 fusion. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2012;18(16):4449–4457.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Ou S-HI, Bang Y-J, et al. Crizotinib in ROS1 -rearranged non–small-cell lung cancer. N Engl J Med. 2014;371(21):1963–1971.
   PubMed Web of Science ®Google Scholar
• Morris TA, Khoo C, Solomon BJ. Targeting ROS1 rearrangements in non-small cell lung cancer: crizotinib and newer generation tyrosine kinase inhibitors. Drugs. 2019;79(12):1277–1286.
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I, Rooney M, Nagy RJ, et al. Molecular analysis of plasma from patients with ROS1-Positive NSCLC. J Thorac Oncol. 2019;14(5):816–824.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Song Z, Wang X, et al. Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant</em>. Onco Targets Ther. 2017;10:4129–4133.
   PubMedGoogle Scholar
• Wu K, Liao X, Gong Y, et al. Circular RNA F-circSR derived from SLC34A2-ROS1 fusion gene promotes cell migration in non-small cell lung cancer. Mol Cancer. 2019;18(1):98.
   PubMedGoogle Scholar
• Yamamoto H, Yoshida A, Taguchi K, et al. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours. Histopathology. 2016;69(1):72–83.
   PubMedGoogle Scholar
• Weidema ME, Versleijen-Jonkers YMH, Flucke UE, et al. Targeting angiosarcomas of the soft tissues: a challenging effort in a heterogeneous and rare disease. Crit Rev Oncol Hematol. 2019;138:120–131.
   PubMedGoogle Scholar
• Bubendorf L, Büttner R, Al-Dayel F, et al. Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch. 2016;469(5):489–503.
   PubMed Web of Science ®Google Scholar
• Charest A, Lane K, McMahon K, et al. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res. 2006;66(15):7473–7481.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist. 2013;18(7):865–875.
   PubMed Web of Science ®Google Scholar
• Rolfo C, Ruiz R, Giovannetti E, et al. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor. Expert Opin Investig Drugs. 2015;24(11):1493–1500.
   PubMed Web of Science ®Google Scholar
• Crizotinib in. ROS1-Rearranged Non–Small-Cell Lung Cancer. N Engl J Med. 2015;372(7):683–684.
   Google Scholar
• Awad MM, Katayama R, Mc Tigue M, et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med. 2013;368(25):2395–2401.
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Loriot Y, Kuo M-S, et al. Crizotinib-resistant ros1 mutations reveal a predictive kinase inhibitor sensitivity model for ROS1 - and ALK -rearranged lung cancers. Clin Cancer Res. 2016;22(24):5983–5991.
   PubMed Web of Science ®Google Scholar
• Lin JJ, Shaw AT. Recent advances in targeting ROS1 in lung cancer.J Thorac Oncol.2017;1611.
   PubMedGoogle Scholar
• Song A, Kim TM, Kim D-W, et al. Molecular changes associated with acquired resistance to crizotinib in ROS1 -rearranged non–small cell lung cancer. Clin Cancer Res. 2015;21(10):2379–2387.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Tseng D, Yoda S, et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non–small-cell lung cancer. JCO Preci Oncol. 2017.
   PubMedGoogle Scholar
• Davies KD, Mahale S, Astling DP, et al. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS ONE. 2013;8(12):e82236.
   PubMed Web of Science ®Google Scholar
• Woo JH, Kim TJ, Kim TS, et al. CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas. Sci Rep. 2020;10(1):16251.
   PubMedGoogle Scholar
• Chen RL,Zhao L, Zhang XC, et al. Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression. BMC cancer . 2018;18:1.
   PubMedGoogle Scholar
• Sgambato A, Casaluce F, Maione P, et al. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors. Expert Rev Anticancer Ther. 2017;18(1):71–80.
   PubMedGoogle Scholar
• He Y, Sheng W, Hu W, et al. Different types of ROS1 fusion partners yield comparable efficacy to Crizotinib. Oncol Res. 2019;27(8):901–910.
   PubMed Web of Science ®Google Scholar
• Wu XY, Wnag YY, Wan SH, et al. Gaining insight into crizotinib resistance mechanisms caused by L2026M and G2032R mutations in ROS1 via molecular dynamics simulations and free-energy calculations. J Mol Model. 2017;23(4):141.
   PubMedGoogle Scholar
• Liu, Yang H, Liu S, et al. Evolution strategy of ROS1 kinase inhibitors for use in cancer therapy. Future Med Chem. 2018;10(14):1705–1720.
   PubMedGoogle Scholar
• Marsault E, Peterson ML. Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. J Med Chem. 2011;54(7):1961–2004.
   PubMed Web of Science ®Google Scholar
• Riggers D, Hale S P, Lee J, et al. The exploration of macrocycles for drug discovery—an underexploited structural class. Nat Rev Drug Discov. 2008;7(7):608–624.
   PubMedGoogle Scholar
• Vendeville S, Cummings MD. Synthetic macrocycles in small-molecule drug discovery. In: Ann Rep Med Chem. 2013;48:371–386.
   Google Scholar
• Basit S, Ashraf Z, Lee K, et al. First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: clinical and designing strategy update of lorlatinib. European Journal of Medicinal Chemistry. 2017;134:348–356.
   PubMed Web of Science ®Google Scholar
• L.J.T.L.C.RAcchinetti FF. Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start. Trans Lung Can Res. 2018;7(S2).
   Google Scholar
• Davare MA, Vellore NA, Wagner JP, et al., Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proc Natl Acad Sci U S A. 112(39): E5381–90. 2015.
   PubMed Web of Science ®Google Scholar
• Zou HY, Engstrom, L. R., Li, Q., et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations Proceedings of the National Academy of Sciences . 2015;112(11):3493–3498.
   PubMed Web of Science ®Google Scholar
• Sun ML, Lee, J. S., Lee, K. H, et al. Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. Journal of clinical oncology . 2017;35(23):2613.
   PubMedGoogle Scholar
• Kim HR, Lim SM, Kim HJ, et al. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol. 2013;24(9):2364–2370.
   PubMed Web of Science ®Google Scholar
• Subbiah V, Hong DS, and F.M.-B.J.P.o.t.N.A.o.S.o.t.U.S.o. America, clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: bench to bedside report. 2016: E1419.
   Google Scholar
• Huang WS, Liu S, Zou D, et al. Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase. J Med Chem. 2016;59(10):4948–4964.
   PubMed Web of Science ®Google Scholar
• Uchibori K, Araki, M., Kamada, M., et al. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat Commun. 2017;8(1):14768.
   PubMed Web of Science ®Google Scholar
• Curtis R, Capelletti M., Kosaka, T., et al. Identification of existing drugs that effectively target NTRK1 and ROS1 rearrangements in lung cancer. Clinical Cancer Research . 2017 23 1 204–213 .
   PubMedGoogle Scholar
• Katayama R, Kobayashi Y, Friboulet L, et al. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clin Cancer Res. 2015;21(1):166–174.
   PubMed Web of Science ®Google Scholar
• Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014;57(11):4720–4744.
   PubMed Web of Science ®Google Scholar
• Ou S, Fujiwara, Y, and Shaw, A. T., et al. Efficacy of taletrectinib (AB-106/DS-6051b) in Nsclc: ROS1+ an updated pooled analysis of US and Japan phase 1 studies. JTO Clinical and Research Reports. 2020
   Google Scholar
• Katayama R, Gong B, Togashi N, et al. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nat Commun. 2019;10(1):3604.
   PubMedGoogle Scholar
• Cui JJ, Zhai D, Deng D., et al. TPX-0005, a supreme ROS1 inhibitor, overcomes crizotinib-resistant ROS1 mutations including solvent front mutation G2032R and gatekeeper mutation L2026M. in Molecular Cancer Therapeutics 17, 2017; Philadelphia, PA. 2018.
   Google Scholar
• TP Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases. WO2015112806A2. 2015
   Google Scholar
• TP Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof. WO2017015367A1. 2017
   Google Scholar
• TP Therapeutics, Inc. Macrocyclic kinase inhibitors and their use. WO2019126122A1. 2019.
   Google Scholar
• Zhejiang Hisun Pharmaceutical Co Ltd. Macrolide derivatives, preparation method and application thereof. WO2020233645A1. 2020.
   Google Scholar
• Primegene Beijing Co Ltd. Diaryl macrocyclic compound and pharmaceutical composition and use thereof. WO2019206069A1. 2019.
   Google Scholar
• Andrews SW. Macrocyclic compounds as ROS1 kinase inhibitors. WO2018170381A1. 2018.
   Google Scholar
• Chengdu Hyperway Pharmaceuticals. A compound as a protein kinase inhibitor and its preparation method and Application. CN112110938A. 2020.
   Google Scholar
• Medshine Discovery Inc. Pyrazolopyrimidine derivative and use thereof. EP3760632A1. 2018.
   Google Scholar
• Array BioPharma Inc. Macrocylic compounds as ROS1 kinase inhibitors. US10688100. 2018.
   Google Scholar
• Shandong Xuanzhu Pharma Co Ltd. Macrocyclic kinase inhibitors and their applications. CN111592541A. 2020.
   Google Scholar
• Shandong Xuanzhu Pharma Co Ltd. Macrocyclic arginine kinase inhibitors and their applications. WO2020094112A1. 2020.
   Google Scholar
• Hangzhou Baixin Biology Medicine Tech Co Ltd. A cyclic aminopyrimidine derivative and its activity and application of inhibiting kinase. CN111269245A. 2020.
   Google Scholar
• Macau University of Science and Technology. Oncogenic ROS1 kinase inhibitor. AU2015100840A4. 2015.
   Google Scholar
• Macau University of Science and Technology. Novel ROS1 inhibitor and its use. AU2015101598A4. 2015.
   Google Scholar
• TYK Medicine, Inc. Compound used as kinase inhibitor and application thereof. WO2020224626A1. 2020.
   Google Scholar
• Janssen Pharmaceuticals, Inc. Compounds as inhibitors of ros1. CN106164076B. 2016.
   Google Scholar
• Janssen Pharmaceuticals, Inc. Compounds as inhibitors of ros1. CN106132967B. 2016.
   Google Scholar
• Daichi Sankyo Co Ltd. Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors. CA2874819A1. 2013.
   Google Scholar
• Janssen Pharmaceuticals, Inc. Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahy-dro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as ROS1 inhibitors. WO2015144799A1. 2015.
   Google Scholar
• Shenyang Pharmaceutical University. Pyrimidine derivatives containing hydrazone and their applications. CN107151233A. 2017.
   Google Scholar
• Shenyang Pharmaceutical University. 2,4-diarylpyrimidine derivatives and their preparation and Application. CN108047204A. 2018.
   Google Scholar
• Shenyang Pharmaceutical University. 2,4-diarylpyrimidine derivatives containing heteroaromatic rings and their preparation methods and Applications. CN111484484A. 2020.
   Google Scholar
• Russian State Pharmaceutical Technology Co Ltd. Novel compounds (variants) and their applications in the treatment of tumor diseases. CN105492445A. 2016.
   Google Scholar
• Hangzhou REX Pharmaceutical Co Ltd. 4-saturated cyclic substituted aniline protein kinase inhibitors. CN106336382A. 2017.
   Google Scholar
• Biotech P. 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-D]pyrimidin-7(8H)-one for treatment of solid cancers. WO2017013160A1. 2017.
   Google Scholar
• Ou S, Tan J, Yun Y, et al. ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway[J]. Expert Rev Anti Infect Ther. 2012;12(4):447–456.
   Google Scholar
• Azel BCM, Sakamoto MR, Bowles DW. ROS1 Targeted Therapies: current Status[J]. Curr Oncol Rep. 2021;23(8):1–9.
   Google Scholar